Newsfeeds - Spark Newswire

3 minute read

FDA
News

Vir Biotech Reports First Marketing Authorization For Its First Commercial Product, Sotrovimab, Granted In Australia

Today, 4:40 PM

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the first marketing authorization, granted in Australia, for its first commercial product, sotrovimab, developed in partnership with GlaxoSmithKline (GSK). This

VIR

1 minute read

Barclays Maintains Overweight on Vir Biotechnology, Lowers Price Target to $71

By Benzinga Newsdesk

Today, 4:40 PM

Barclays analyst Gena Wang maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and lowers the price target from $96 to $71.

VIR

1 minute read

Vir Biotechnology Q2 EPS $0.48 Beats $(0.48) Estimate, Sales $177.10M Beat $84.56M Estimate

By Bill Haddad

Today, 4:40 PM

Vir Biotechnology (NASDAQ:VIR) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $(0.48) by 200 percent. This is a 277.78 percent increase over losses of $(0.27) per share from

VIR

34 minute read

Earnings Scheduled For August 5, 2021

By Benzinga Insights

Today, 4:40 PM

Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.

AAOI

1 minute read

Vir Biotechnology Starts Dosing In Mid-Stage Hepatitis B Trial With Combination Therapy

By Vandana Singh

Today, 4:40 PM

Vir Biotechnology Inc (NASDAQ:VIR) has dosed the first patient in the Phase 2 MARCH trial evaluating VIR-2218 in combination with VIR-3434…

VIR

1 minute read

Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating Combination Of VIR-2218 And VIR-3434 As A Functional Cure Regimen For Chronic Hepatitis B Virus Infection

By Bill Haddad

Today, 4:40 PM

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the first patient has been dosed in the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial evaluating VIR-2218

VIR